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Abstract
Hepatic fibrosis occurs in response to persistent liver damage and is character-
ized by an excessive accumulation of extracellular matrix. When the damage is
prolonged, there is a chronic inflammation and persistent hepatic fibrosis eventu-
ally leads to cirrhosis, where in addition to the scar, there is an important vascular
remodeling associated with portal hypertension and, if decompensated, leads to
death or can develop hepatocellular carcinoma. We have been studying the phar-
macologic functions of adenosine, finding that a derivative of this nucleoside, IFC-
305, shows hepatoprotective effects in a CCl4-induced rat cirrhosis model where it
reverses liver fibrosis through modulation of fibrosis-related genes and by amelio-
rating hepatic function. Furthermore, this compound has the property to rescue cell
cycle inhibition in vivo, prevents hepatic stellate cell activation, modulates anti-
inflammatory macrophage polarization, and favors a chromatin context that could
decrease the genomic instability and characteristics of cirrhosis, enabling the
recovery of gene expression profile. Here we show results that contribute to the
comprehension of molecular and cellular mechanism of cirrhosis, give the opportu-
nity to suggest biomarkers to the early diagnostic of this pathology, and constitute
the fundaments to suggest IFC-305 as a coadjuvant for treatment of this disease.
Keywords: liver fibrosis reversion, adenosine, Kupffer cells, hepatic stellate cells,
cell cycle, epigenetics
1. Introduction
Cirrhosis is the 14th dead cause worldwide in adults [1]; this pathology represents
an hepatocellular alteration, which is defined histologically by a vascular remodeling
that triggers formation of fibrotic interconnected septum that wraps the entire liver
tissue and divides the parenchyma in nodules [2]; as a consequence, there is a
reduction in hepatocellular mass as well as liver function and blood flow alterations.
These pathologic characteristics are independent of disease etiology, which mainly
could be alcoholic, biliary, and directed by viral or chronic hepatitis [3].
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In the past, cirrhosis was considered as an irreversible illness, but there is
evidence, which suggests that when there is an arrest of the viral or nonviral mayor
cirrhotic-generator insult, it is possible to resolve fibrosis [4–9]. This is evident in
successfully chronic hepatitis C treatment, in fibrosis resolution in hemochromato-
sis patients with effective treatment, and also in alcoholic liver illness patient who
has suspended alcohol consumption [10]. A group of histopathological injuries of
“reverted cirrhosis” has been described in the “hepatic reparatory complex” [9]
including a thin, incomplete and perforated septum, through which hepatocytes are
evident; there is a hepatocyte growing in terminal hepatic venules and little cumu-
lus of thick collagen fibers in the parenchymal sinusoids [2]. Nevertheless, this
disease could be considered as a pre-neoplastic state considering that 80% of hepa-
tocellular carcinoma originated from cirrhosis [11].
This pathology is a silence one; generally it courses without symptoms, whereby
its development confers a significant morbidity and mortality risk, and progression to
this terminal state of chronic liver injury is slow, around 20–40 years [12]. Thanks to
advances in the understanding of chromatin organization and rapid progress in
sequencing technology, it has been clear that not only genetics but also epigenetics
influence both normal human biology and diseases [13]; the combinatorial of these
both factors could influence on speed of disease development, generating changes in
chromatin, an inflammatory process and hepatic stellate cell (HSC) activation, trig-
gering a pro-fibrotic environment and if it is perpetuated, the cirrhosis establishment.
In this section, we will get deep into molecular and cellular aspects of cirrhosis and
how an adenosine derivative could reverse this pathology through generating an anti-
inflammatory environment and blocking HSC activation, modulating cell cycle and
mediating epigenetic changes which reduce altered expressed genes.
2. Biochemical and physiological alteration of liver during cirrhosis and
hepatoprotective effects of an adenosine derivative
Cirrhosis has a complex cellular and molecular dynamic that should be
approached using laboratory models that could be animal or cell cultures. One of the
most studied cirrhotic models employs carbon tetrachloride (CCl4) to generate the
pathology. This compound is a hepatic and renal toxic, whose effect is produced by
two different mechanisms: the first one is related with the alteration of hepatocyte
capacity to bind triacylglycerides to transporter lipoproteins, triggering an intracel-
lular lipid accumulation and fatty degeneration of the liver; the second mechanism
consists in the formation of metabolites extremely toxic, which lead to cell death
and centrilobular hepatic necrosis [14]. This toxic compound is a substrate of P450
cytochrome that transforms it into CCl3 radicals, and these radicals generate
CCl3OO when it reacts with molecular oxygen. Since CCl3 radicals react with cell
membranes inducing lipid peroxidation, it has been proposed that the main cause of
hepatic illness by CCl4 is the membrane damage by the free radical chain reaction,
and probably, the initial event is related with mitochondrion membrane damage
[15]. Nevertheless, it is important to say that this model, unlike what happens in the
human, progresses to hepatocellular carcinoma with low frequency, so that it per-
mits only the evaluation of cirrhotic state.
Rats are intraperitoneal treated with 0.04 g/kg body weight of CCl4 three times
per week, during 10 weeks. After this time it is possible to observe a liver distortion,
the formation of nodules, bilirubin accumulation and hepatomegaly [16], the gen-
eration of a fibrotic area of 16% of the tissue, and a reduction in parenchyma surface
to around 78%. As a consequence of these liver architecture changes, there are
alterations of liver function: serum samples of cirrhotic rats display elevated AST,
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ALT, and bilirubin levels and albumin are relatively reduced [17]. Furthermore,
there is a reduction in ATP level with slow recovery after 5 weeks with saline. All of
these altered parameters reflect chronic hepato-biliary injury.
Since 1967, our laboratory has been studying the pharmacologic effects of adeno-
sine on hepatic metabolism [18], finding that this nucleoside increases hepatocyte
energetic charge [19], an effect which is able to increase metabolic fluxes [20]; it
increases glycogen synthesis, blocks fatty acid oxidation [21], and maintains cell
redox state. Some of the pharmacologic effects of adenosine on hepatotoxicity are:
prevention of fatty liver disease [21], recovery of basal energetic state which was
reduced by toxic agents [22], maintenance of redox balance between cytosol and
mitochondrion [23], prevention of CCl4-induced necrosis [24], avoiding free radical
propagation during CCl4 metabolism [25], and modulation of the blood flux of
hepatic artery [23]. Furthermore, adenosine is able to reduce 50% collagen accumu-
lation in a cirrhosis prevention model, thanks to the increase of liver collagenolytic
activity hand by hand with an improvement of liver function [26–31]. These findings
allowed us to propose adenosine as possible treatment to reverse cirrhosis.
In order to understand the mechanism of action of adenosine, we generated
several derivatives and compared their hepatoprotective properties against adeno-
sine, because this nucleoside is subject of an active metabolism within the cell
resulting in a short half-life of the nucleoside but with capability of metabolic
modulation; it could be phosphorylated by adenosine kinase, deaminated to inosine
by adenosine deaminase, or transformed to S-adenosylhomocysteine by S-
adenosylhomocysteine hydrolase [32].We found that aspartic salt of this nucleoside,
now denominated IFC-305, presents a better protection against lethal dose of CCl4
using a fourth of the dose than the parental compound; this effect could be under-
standable because IFC-305 presented a delay in the maximal absorption than aden-
osine (20 vs. 30 min), but adenosine level rapidly declined to practically
undetectable levels between 60 and 120 min, while IFC-305 presented a significant
liver concentration even 120 min after its administration; this behavior could be
explained by a 20% diminution of the activity of the adenosine deaminase, in the
presence of IFC-305, an enzyme responsible to transform adenosine to inosine.
These results suggest that IFC-305 clearance is much slower than that of adenosine
[33]. With these results, we decided to explore the hepatoprotective properties of
this adenosine compound, treating rats (50 mg/kg body weight, three times per
week) during 5 weeks after cirrhosis induction with CCl4.
Cirrhotic rats treated with IFC-305 present a healthy-like liver phenotype com-
pared with cirrhotic rats and also with cirrhotic rats treated with saline during
5 weeks after cirrhosis induction. Besides, decreased fibrosis was evident in
response to IFC-305 treatment, accelerating fibrosis resolution, leaving only 4% of
fibrotic area, while increasing parenchymal liver area from 87 to 90%, and collagen
was decreased to half-level as compared to saline-treated rats. This improvement in
liver architecture was in accordance with liver physiological amelioration; IFC-305
reduced significantly bilirubin and serum transaminase activities [17], and ATP
levels were equivalent to those of healthy liver [34], corroborating that IFC-305
presents the same hepatoprotective properties reverting cirrhosis than adenosine
but with a lower dose.
3. Cell cycle inhibition during cirrhosis and its recovery by IFC-305
Liver has a well-known capability to regenerate after resection [35]; the severity
of liver fibrosis is considered to be related with impaired regenerative capacity,
suggesting the arrest of cell cycle [36]. The fibrogenesis process is accompanied by
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energetic imbalance as well as oxidative damage generated by oxygen species that
could result in chromosomal instability, which induces injury in the check points of
the cellular cycle triggering an impaired regenerative capacity [34].
Cell cycle molecules play essential roles in hepatocyte proliferation. Specifically,
G1-phase related molecules are important because they are a requisite to enter into
cell cycle from quiescent state [34]. Considering adenosine is able to increase DNA
synthesis as well as the mitotic index and the expression of proliferating cell nuclear
antigen (PCNA) in a pre-established cirrhosis [31], over and above accelerating
progression of cell cycle during liver regeneration in rats subjected to one-third
hepatectomy [37], we have explored cell cycle state during cirrhosis and changes
mediated by IFC-305.
During cirrhosis, there is no evident change on PCNA, which is an auxiliary
protein of DNA polymerase delta and is an excellent marker of cell proliferation and
it is present at the beginning of the S phase; but IFC-305 treatment generates a 10-
fold increase of this protein, supporting the effect on proliferation activation medi-
ated by this compound; this result was validated by immunohistochemistry [34].
Regarding cell cycle cyclins, cyclin D1 levels in cirrhotic state was not altered, but
treatment with IFC-305 showed a 77% protein increase; this behavior correlates
with expression levels of that cyclin. On the other hand, Cyclin B1 did not change in
cirrhotic rats, but IFC-305 treatment reduces by 30% the protein level [34]. Cyclin
D1 belongs to G1 phase and is fundamental to initiate cell cycle and requires the
association with cyclin-dependent kinase 4 or 6 (CDK4/CDK6) to form an active
complex and allows the progression of cell cycle to S phase, whereas degradation of
cyclin B1 is important for metaphase-anaphase transition and progression of cell
cycle [38]. Evaluating the levels of CDK4, we did not find changes in cirrhosis but
IFC-305 generates a high increment of this protein. In the case of CDK6, the protein
is present in cirrhosis, the cessation of CCl4 and saline solution administration
reduces its levels, meanwhile IFC-305 treatment maintains elevated the presence of
CDK6 [33]. These results suggest that both CDK4 and CDK6 could form a complex
with Cyclin D1 and favor cell cycle progress in response to IFC-305 treatment. The
complex Cyclin D/CDK4/6 is responsible for Rb protein phosphorylation, promot-
ing the release of E2F1, which can induce transcription of several genes involved in
cell cycle entry into S phase and induction or inhibition of apoptosis [39]. In livers
from cirrhotic rats, there is a reduction of phospho-Rb (Ser 795), and IFC-305
restores the healthy levels; Rb gene expression correlates with protein levels. Analysis
of E2F1 protein levels reveals a decrease of this protein in cirrhotic livers and admin-
istration with saline solution during 5 weeks after cirrhosis inductions partially
reestablishes the levels of that protein but IFC-305 generates a higher increment than
the one reached with saline; this increment together with Rb gain supports the
reactivation of cell cycle, suggesting the entry to S phase of cell cycle [34].
Another level to regulate cell cycle progression is related with its inhibitors; with
regard to this, p21 is reduced 40% in cirrhotic animals and IFC-305 is able to
reassemble the healthy liver levels; p27, another cell cycle inhibitor, did not show
effects that could be related with cirrhosis establishment neither to IFC-305 treat-
ment during 5 weeks [34], so it is possible to suggest that one of the key cell cycle
inhibitors in cirrhosis development is p21.
Trying to understand which could be the signal that generates this reactivation
of cell cycle, we evaluated hepatocyte growth factor (HGF) levels in serum and
liver; HGF originally identified and cloned as a potent mitogen for hepatocytes, is a
strong protective and trophic factor for many tissues and organs [40]. Since HGF is
produced mainly by mesenchymal cells and c-Met, its specific receptor tyrosine
kinase is expressed in most epithelial, endothelial, and somatic stem cells [41]. In
cirrhosis, there is a little increment of HGF in serum but in liver, there are no
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significant changes; meanwhile, rats treated with IFC-305 trigger a threefold
increase of serum HGF versus healthy animals and a 35% increase versus cirrhotic
animals; in liver, there is a trend to increase the levels of HGF compared with both
healthy and cirrhotic rats. On the other hand, c-Met receptors present a 25%
increase in cirrhotic animals with further increase after 5 weeks of progress, but
treatment with IFC-305 induced a diminution in relation with cirrhotic rats admin-
istered with saline [34]. With these results, we could suggest that IFC-305 is able to
increase HGF levels in serum of cirrhotic rats, which could interact with c-Met in
liver, being the mitogenic signal which could trigger the reactivation of cell cycle
recovery.
4. Inflammation, the beginning of liver disease and a key of IFC-305-
mediated cirrhosis resolution
In recent years, it has been demonstrated that the immune response is one of the
main mechanisms involved in the progression and repair of liver pathologies [42].
Liver injuries provide a proper model of inflammation and repair, showing a
complex interaction of parenchymal, no-parenchymal cells and the extracellular
matrix, all of them, components of the mammalian wound-healing response. In
almost all etiologies, cirrhosis is preceded by fibrosis and inflammation, with ele-
ments of innate and adaptive immune response that are crucial in regulating these
processes [43]. Recent efforts to confront these fibrotic diseases are focused on
finding specific marks that transform an acute inflammation to a chronic one, and
to use them as therapeutic aims for treatment and reversion of this phenomenon
[44]. The immune response plays an essential role in this transformation, mainly by
diverse cellular phenotypes [45]. The participation of immune cells, such as Kupffer
cells (KCs), the liver macrophages, as initial effectors, is one of the main responsible
of cirrhosis development [46, 47]. They are antigen presenting cells and represent
an immune cell population related to liver fibrosis treatment.
The KCs present diverse activation phenotypes: M1 related to inflammation and
M2 anti-inflammation related with resolution of inflammation processes [48–50],
both are regulated by extracellular signals such as adenosine [51] and are directly
connected with other immune cells types as B and T cells.
In liver diseases, the phenomenon, in a canonical way, occurs when the activated
KCs regulate the hepatic stellate cells and other molecular and cell interactions
associated with the establishment of cirrhosis [52, 53]. KCs also interact with other
cells, like neutrophils, hepatocytes, etc., mainly through molecules directly associ-
ated with inflammation, tissue damage, and fibrosis, like cytokines and
chemokines, such as IL-1β, IL-6, TNF-α, and MCP-1 [54] or ROS (reactive oxygen
species) which promote the inflammatory response; KCs could be contributing to
anti-inflammatory effects with IL-10 and other cytokines involved in tissue repair
[55]. The liver is the main organ that produces and removes cytokines; all cell types
in the liver are capable of cytokine production, parenchymal and non-parenchymal
cells [56, 57].
By their destructiveness, macrophages guide the course of the inflammatory
response and are involved in the synthesis and repair of damaged tissue during the
inflammatory process, participating actively in the resolution of inflammation [58].
There are two proposed macrophage subtypes; activated by two ways: the classical
pathway (M1) or the alternative pathway (M2) [59]. These different polarization
states will depend on the microenvironment and the source of damage that has
occurred. The classical activation is critical for the initiation and maintenance of the
inflammatory process and to the response against pathogens and immune response.
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Classical activation or M1 is produced by the interaction of TLR4 receptor with
PAMPs such as LPS, from Gram-negative bacteria wall or by specific cytokines such
as TNF-α or γ-IFN. This group of classically activated macrophages produces large
amounts of proinflammatory cytokines such as TNF-α, interleukins (IL-1β, IL-6,
and IL-12), proinflammatory chemokines such as MCP-1, and nitric oxide (NO),
promoting activation, migration of other cells, and tissue damage [58].
In the case of alternative activation, the Th2 cells secrete cytokines such as IL-4
or IL-13 and induce the macrophage alternative M2 phenotype [60]. These M2
macrophages have very little capacity to present antigens while secrete high levels
of anti-inflammatory cytokines such as IL-10. Unlike classical activation, these
macrophages are not able to produce nitric oxide from L-arginine and also fail to
control the growth of intracellular pathogens [61]. However, they are capable of
producing a high quantity of arginase 1 enzyme that metabolizes L-arginine to
produce proline, glutamate, and polyamines promoting tissue repair [62].
We have demonstrated that in the experimental model of CCl4-induced cirrho-
sis, the IFC-305 treatment generates several changes in the inflammatory process,
mediated by cytokines and immune cells [63]. During the development of cirrhosis,
we observed an increment in the liver inflammatory cytokines, IL-6, IL-1β, MCP-1,
and TNF-α, in plasma and liver tissue, as well as an increment of M1 macrophages
(CD163+/CD11b+). The IFC-305 treatment decreased these inflammatory cyto-
kines, reduced the M1 inflammatory macrophages, and increased the M2 anti-
inflammatory macrophages (HIS36+/CD11b+). The anti-inflammatory role of IFC-
305 was also supported by elevation of IL-10, an enhanced metabolic activity of
arginase, reduction of NO levels in serum rats, a diminution of the protein levels of
inducible nitric oxide synthetase, and an increment of the protein levels of arginase
1 in the liver. These results suggest that the IFC-305 modulates the immune
response in cirrhosis and supports the hepatic protective action through an anti-
inflammatory role, mainly mediated by Kupffer cells [64].
5. Hepatic stellate cells, generators of extracellular matrix components
which trigger fibrosis and its activation prevention by IFC-305
Liver fibrosis is characterized by an accumulation of collagen types I and III
that are secreted by liver myofibroblast. These cells are originated mainly from
hepatic stellate cells (HSCs) and in a less number from the periportal fibroblast
or bone marrow cells. In normal liver, HSCs represent almost 10% of all resident
cells of the liver. They are quiescent cells specialized in lipid storage, mostly
retinyl esters. When there is a liver damage, the HSC become activated or
transdifferentiate to myofibroblast phenotype, characterized for being
proliferative, pro-inflammatory, and contractile and for increased synthesis of ECM
proteins [65].
The activation of HSCs is promoted by stimuli from resident and infiltrating
inflammatory cells that produce fibrogenic, proliferative, and inflammatory cyto-
kines such as TGF-β, PDGF, and TNF-α, among others, in addition to reactive
oxygen species [65].
In order to clarify the hepatoprotector role of IFC-305 in the CCl4-induced liver
fibrosis at a molecular and cellular level, we explored the effect of IFC-305 on the
activation of HSCs. These cells isolated from normal rat livers become activated
in vitro after 7 days in culture, in a similar manner that occurs in vivo after a liver
injury. We isolated HSCs from normal rat livers and cultured them for 7 days.
We found that IFC-305 treatment suppresses their activation, determined by the
inhibition of Col1a1 mRNA expression, prevention of Rho activation, inhibition of
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PDGF-stimulated proliferation, and increased expression of anti-fibrogenic genes
such as Pparg, Smad7, and Mmp-13 [66].
Hepatic fibrosis is characterized by ECM deposition, specially the type I collagen
protein. The excess of ECM is due to an imbalance between its production and its
degradation. ECM degradation is carried out by matrix metalloproteinases (MMPs),
whose activity is negatively regulated by tissue inhibitors of matrix metallopro-
teinases (TIMPs). During progression of liver fibrosis, activated HSCs produce an
excess of ECM and increase the expression of TIMP-1 and TIMP-2, resulting in an
excess of ECM deposition. In rodents, the MMP-13 is the principal matrix
metalloproteinase that degrades type I collagen [67]. Treatment of HSCs with IFC-
305 inhibited the production of Col1a1 mRNA but also increased the expression of
Mmp13 mRNA, which may result in an important decrease of collagen deposition.
The main fibrogenic cytokine is TGF-β, which signals into the cell through
membrane kinase TGF-type I and type II receptors, which activate the intracellular
Smad proteins and transduce the TGF-α signal to the nucleus. The Smad 7 acts as a
negative regulator of this pathway [65]. The Smad7 mRNA expression induced by
IFC-305 could result in the inhibition of TGF-β signaling and inhibition of HSC
activation.
Peroxisome Proliferator Activated Receptor gamma (PPARγ) regulates cellular
fatty acid storage and adipogenesis of fibroblast. Another very important effect of
IFC-305 on HSC is an increase of PpargmRNA expression. PPARγ is expressed in
quiescent HSC, and its expression is rapidly decreased during HSC activation
in vitro and in vivo [68]. It is well documented that expression of PPARγ or treat-
ment with its natural or synthetic ligands inhibits HSC activation or can reverse the
activated HSC phenotype to the quiescent one [69]. The increased expression of
Pparg mRNA with IFC305 in HSCs could be contributing to maintain their quies-
cent phenotype.
The IFC-305 also inhibited the PDGF-BB-stimulated proliferation of HSC;
exploring the mechanism, we found that this effect was independent of adenosine
receptors, but required their uptake into cells by adenosine transporters followed by
their intracellular conversion to AMP by adenosine kinase, leading to increased
levels of AMP, pyrimidine starvation, and inhibition of DNA synthesis [66].
In summary, we demonstrated that HSCs are an important target of the anti-
fibrotic role of IFC-305 contributing to its hepatoprotective effect on liver fibrosis.
6. Gene expression deregulation in cirrhosis and IFC-305 modulation
beyond genetics
With the interest to have a general view of molecular changes occurring in
cirrhosis, we assessed the transcriptome evaluation of both cirrhotic and cirrhotic
livers treated with IFC-305 and found 413 deregulated genes in cirrhosis, and IFC-
305 treatment reduces the genes with deregulated expression to 263; making a gene
ontology, we noticed that the highest proportion of deregulated genes is related
with signal transduction, and interestingly, some of these deregulated genes are
involved in TGF-β signaling pathway, lipid metabolism, urea cycle, and
fibrogenesis.
Validating some of these differential expressed genes, we found an over-
expression of Fn1 (fibronectin 1) and Col1a1 in cirrhosis; both of them are regulated
by TGF-β signaling pathway, and importantly, Col1a1 gene encodes a component of
type I collagen called the pro-α1(I) chain that constitutes one of the main ECM
proteins in the fibrotic liver. In fact, expression of Tgfb1 gene was also increased in
cirrhosis, and other two genes with the same behavior were the complement C9 and
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Apoa1 [17]. PPARγ has anti-fibrogenic activity inhibiting collagen I transcription
[70]; there was a reduction in transcript levels of Pparg gene in cirrhosis state, in
concordance with other reports [71, 72]. Transcriptome analysis also revealed three
genes involved in ornithine and urea metabolism; the transcript level ofAss1 gene was
reduced as well as Cps1 gene. Making a deeper analysis of the transcriptome data, we
could identify a chromatin-related gene deregulated in cirrhosis; HDAC3 histone
deacetylase is over-expressed during cirrhosis. IFC-305 is able to reduce the levels to
healthy-like levels for three fibrogenic genes (Fn1, Col1a1, and Tgfb1), C9, Apob1 and
Hdac3;meanwhile, this compound generates the increasing expression of Pparg and
Cps1 recovering the levels of the healthy liver and partially restoring the levels of Ass1
[17]. Analyzing proteins, we could identify an increment in collagen I and HDAC3
and a reduction of PPARγ during cirrhosis, and the treatment with IFC-305 resembles
the healthy-like levels of these three proteins [16]. Thus, through this quantitative
analysis of expression and protein levels, IFC-305 shows capabilities to modulate the
gene expression of some important genes involved in liver fibrogenesis.
During CCl4-induced cirrhosis, besides hepatocellular damage previously
mentioned, there is chromosome instability [73] that could be induced by
hypomethylation on DNA, and contributes to carcinogenesis [74]. Considering
cirrhosis as a pre-neoplastic state (because 80% of hepatocellular carcinoma cases
are preceded by cirrhosis) [11], it is possible that the big changes in gene expression
could be directed by chromosomal instability generated by CCl4, but beyond the
genetic alterations that probably are occurring, many of these changes could be
related to regulation of gene expression at epigenetic level even more because
chromosomal instability could be occurring by DNA hypomethylation. Also, it is
important to remember that HDAC3 was incremented in cirrhosis, so some changes
in gene expression could also be modified by changes in chromatin.
Every process which is able to influence in heritable gene expression without
affecting DNA sequence is considered as an epigenetic regulation process [75]. DNA
methylation is probably the most studied epigenetic modification [76, 77]; it con-
sists in the incorporation of methyl group in 5 position of cytosine from CpG
dinucleotide. This incorporation does not modify DNA sequence and can influence
directly in transcriptional activity [78]. Methylated DNA distribution along genome
shows an enrichment on noncoding regions, repetitive elements [75], and further, it
inactivates mobile elements of the genome as transposons and sequences of viral
origin, having a function in genome stability maintenance, blocking undesired
recombination events [76]. On the other hand, on CpG islands of active genes, there
is no enrichment of this DNA modification [75] and participates in permanent gene
silencing in different steps of development [78, 79]. DNAmethylation is directed by
DNA methyltransferase enzymes which use S-adenosylmethionine (SAM) as
methyl donor from methionine cycle and the product of this reaction is S-
adenosylhomocysteine (SAH). It is important to mention that one important factor
to modulate biological methylation reactions (to DNA, RNA, proteins, and phos-
pholipids) is the hepatocellular ratio SAM/SAH [80].
The discovery of an active DNA demethylation pathway that involves the con-
version of 5mC to oxidized forms, like 5hmC, by DNA dioxygenases TETs and DNA
repair through the base excision system, incorporates a dynamic reversibility of
DNA methylation [81–84]. Ever since the discovery of this dynamics, strenuous
efforts have been made to characterize the precise role of 5hmC; such roles are
becoming more evident as we learn about 5hmC-specific genomic localization, its
relative stability, and recognition by other proteins [85], and current studies have
shown that this DNA modification has an antagonic role to 5mC [86].
We have previously shown that adenosine can modulate trans-methylation
reactions, like methylation of phospholipids, via regulation of
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S-adenosylmethionine (SAM) levels [87], so that we make an approach to SAM
levels and found that during cirrhosis, the amount of this molecule is diminished,
whereas IFC-305 treatment restored the physiological levels; this suggests that
during cirrhosis, it could be an imbalance of methylation reactions, and IFC-305,
like adenosine, could also regulate this process [16].
Epigenetic changes in cirrhosis are little understood; some studies demonstrated
a reduction on DNA methylation through the genome in CCl4-induced cirrhosis
[15, 88], and analyzing in a global way this modification, we obtained the same
behavior. With these results and in order to assess DNA methylation dynamics,
5hmC levels were measured and a similar behavior to the one observed with 5mC, a
reduction of 5hmC in cirrhosis in concordance with group of Mann findings, was
found [89]. Treatment with IFC-305 triggers a regaining of both 5mC and 5hmC
[16]. These results together suggest that there is a perturbation of DNA methylation
dynamic during cirrhosis, while IFC-305 is able to modulate this dynamic, possibly
reducing chromosome instability.
Another level of epigenetic regulation is related with genome packaging in chro-
matin, which has a direct repercussion in transcriptional activity, being mandatory its
remodeling, space specifically, and in a time defined way to carry out gene expression
[90]. Histones are a fundamental component of chromatin structure, being a target of
a big variety of post-translational modifications (PTMs), which allows the formation
of particular and regulated chromatin states; furthermore these modifications could
be inherited post-mitotically [91]. We want to highlight among histone PTMs, lysine
acetylation. DNA association with histone core is facilitated by electrical charge dif-
ference between both molecules, but histone acetylation neutralizes lysine positive
charge, weakening nucleosome-DNA interaction and triggering a less compact con-
formation which favors transcription [92].
Considering the finding that histone deacetylase HDAC3 level was high during
cirrhosis, global histone H4 acetylation was assessed, finding a reduction in this
histone PTM in cirrhotic livers. Physiological levels of global histone H4 acetylation
in cirrhotic rats treated with IFC-305 were recovered [16]. Together, these results
suggest that deregulated gene expression during cirrhosis could be related with
epigenetic deregulation involving DNA methylation dynamics and changes in his-
tone acetylation; besides, IFC-305 has epigenetic properties being able to modulate
5mC, 5hmC, and histone H4 acetylation in a global way, favoring the recovery of
physiological levels of each epigenetic modification and triggering the rescue of
healthy-like gene expression in liver.
7. Getting deeper into cirrhosis resolution or epigenetic regulation of
Pparg and Col1a1 by IFC-305
Once established that IFC-305 is able to reverse fibrosis, reactivating cell cycle
progression in cirrhotic livers, favoring an anti-inflammatory environment,
blocking hepatic stellate cell activation, and regulating gene expression through
epigenetic modulation, we analyzed the regulation of two of the main genes with
modified expression during cirrhosis, Pparg and Col1a1. Reminding, collagen I is the
mayor ECM protein and responsible for liver fibrosis, Col1a1, a gene which encodes
pro-α1 chain of this protein is over-regulated in cirrhosis, and there is a reduction of
nuclear receptor PPARγ in this pathological condition.
PPARγ has antifibrotic properties because it is able to inhibit collagen I gene
transcription. This inhibition is mediated by the ability of nuclear receptor to
compete with NF-I/p300 association to the Col1a1 gene in HSC [70]. p300 has a
histone acetyltransferase activity that transfers an acetyl group to the lysine residue
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[93] generating an open chromatin context in Col1a1 gene promoter favoring its
expression; whether PPARγ replaces p300 in Col1a1 gene promoter, there is a
chromatin context change because of the loss of acetylation activity in this region,
and the consequent blocking of the gene expression.
On the other hand, regulation of Pparg expression is directed by MeCP2 protein
in HSC activation like in cirrhosis. MeCP2 binds to regulatory regions of the gene
which are CpG enriched and recruits histone H3K9me3 writer enzymes suppressing
initial transcription of the gene. Furthermore, MeCP2 is required for polycomb
repressor complex 2 EZH2 component that establishes histone H3K27me mark on
the downstream coding gene region, blocking transcription elongation [94]. This
mechanism could explain the reduction of PPARγ levels in cirrhosis and therefore
the over-expression of Col1a1 in cirrhosis.
Considering that MeCP2 is a methyl binding protein [94], DNA methylation state
was evaluated with sodium bisulfite DNAmodification on Pparg gene promoter, and it
was found that both healthy and cirrhotic livers present Pparg gene promoter without
DNA methylation, and IFC-305 treatment does not modify this nonmethylated state
[16]. Evaluating histone H4 acetylation and histone H3K27me3 on Pparg gene pro-
moter through chromatin immunoprecipitation assay, we found that in cirrhosis,
there is a trend to compact chromatin context mainly dictated by histone H4 acetyla-
tion reduction, which correlates with decreased expression and protein levels; after
treatment with IFC-305 chromatin, there is an open chromatin context on Pparg gene
promoter triggered by an increase on histone H4 acetylation and a reduction of histone
H3K27me3, going hand by hand with over-expression and increase of protein levels
[16]. These findings suggest that reduction of PPARγ on cirrhosis is coordinated by a
chromatin compaction on gene promoter, and IFC-305 treatment generates a
decompaction of gene promoter with the consequent increase of gene expression.
The next step was to identify if IFC-305 mediated fibrosis reversion is related
with Col1a1 gene expression blocking though PPARγ was to assess nuclear receptor
deposition on Col1a1 gene promoter, but we were not able to find an increment of
this interaction in whole cirrhotic tissues treated with IFC-305; rather, we found a
diminishment of PPARγ deposition [16]. Further experiments on isolated HSCs
treated with IFC-305 are required to know if this molecular mechanism is occurring
directly in responsible cells of fibrosis generation. So, we asses DNA methylation
state on Col1a1 gene promoter, to know if this epigenetic mechanism is involved in
regulation of gene expression during cirrhosis. In healthy liver, Col1a1 gene pro-
moter presents a methylated state, which correlates with the absence of collagen I
overproduction; in cirrhosis state and progress of the illness, there is an important
reduction on methylation state on Col1a1 gene promoter going hand by hand with
accumulation of collagen I; and finally, treatment with IFC-305 generates a
remethylation of gene promoter and an enrichment of methylation around tran-
scription start site, associated with collagen reduction.
With these results, we could propose that fibrosis generation could be directed
by loss of DNAmethylation on Col1a1 gene promoter, and one of the mechanisms of
action that could explain cirrhosis resolution mediated by IFC-305 is the modulation
of DNA methylation on Col1a1 gene.
Blocking the prelude of hepatocellular carcinoma, a key point to avoid chronic
liver injury progress.
Along this chapter, some cellular and molecular alterations that characterize
cirrhosis have been described: a pathology that results in the combination of factors
which alters liver environment, beginning with an immunological response origi-
nated by macrophages inflammatory polarization that triggers hepatic stellate cell
activation, with alterations at chromatin level resulting in chromosome instability
and altered gene expression favoring the fibrogenic process. All these changes, as a
whole, could facilitate progress of the illness to hepatocellular carcinoma (HCC),
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which is the most common primary carcinoma of the liver. Up to 85% of HCC cases
arise in chronically inflamed and subsequently cirrhotic livers [95].
According to GLOBOCAN-IARC datasets [96], liver cancer is estimated to be at
the 7th place of cancer incidence and the 4th cancer death cause in 2018. Consider-
ing cirrhosis as a prelude of HCC, it is understandable that many liver cancers
follow a pattern of pathologic evolution, starting from cirrhosis to low-grade dys-
plastic nodules, high-grade dysplastic nodules, early HCC, progressed HCC and,
finally to advance HCC. Furthermore, this progress of illness involves a more
evident imbalance between genetic and epigenetic factors; regarding genetic ones,
early dysplastic nodules present a genome with a very limited genetic variation,
while advanced HCC has a heterogeneous genome with a range of 72–182 mutations
[97, 98]. On the other hand, concerning epigenetic aspects, a genome-wide DNA
hypomethylation in HCC has been described, which could be indicative of poor
survival [99]. In the same sense, another study described that aberrantly methyl-
ated differential expressed genes are related with cell cycle progress, p53 signaling,
and MAPK signaling in HCC [100]. Alteration on DNA methylation state could be
explained by down-regulation of TET dioxygenases in HCC condition with the
consequent reduction of 5hmC levels [101]. In normal tissue there is a characteristic
difference between euchromatic and heterochromatic regions that is lost in cancer
condition; it has been suggested that lost could be generated by a reduction of 5hmC
levels which goes around 70%. Furthermore, the specific relationship between
5hmC and chromatin marks in normal tissue is largely erased in tumors and sug-
gests that 5hmC landscape change in cancer could be associated with chromatin
structure alterations and deregulation of gene expression during tumorigenesis
[102].
HCC may progress silently in patients with sufficient liver function; due to
vague complaints and nonspecific symptoms, HCC diagnosis is usually delayed
[103]. Selected patients with localized disease may be treated with curative intents
with resection, liver transplantation, or local therapy like radial frequency ablation,
chemoembolization or radio-embolization. However, the majority of patients with
HCC are not candidates for resection [104, 105]. For patients suffering from
advanced HCC, chemotherapy failed to demonstrate a survival advantage
[106, 107]; so far, sorafenib is the first and only target orientated agent approved as
therapy of HCC [105], but it only extends survival of patients with advanced stage
disease for 3 months, and this medication causes considerable adverse events and
offers no symptom palliation [108]. This lack of effective treatment and surgical
impediment highlights the importance to reinforce molecular target therapies.
Preclinical studies indicated that IFC-305 is not toxic, neither genotoxic, nor
teratogenic and it is anti-carcinogenic [33]. Considering this last property, we
assessed IFC-305 effects on a chronic model of liver intoxication with diethylni-
trosamine and found that it could act as a HCC chemopreventive agent [109, 110].
The above suggests that some anti-fibrotic effects of the compound could prevent
cancer development, being an adjuvant in chronic liver disease treatment. Cur-
rently we are studying a deep molecular level to identify IFC-305 mechanism of
action in prevention of cancer establishment and potential disease reversion.
Considering recent advances in cirrhosis knowledge, we could suggest that in the
not long future, drugs targeting specific molecular keys for cirrhotic and HCC will be
developed and potentially they could be the first line of treatment even after surgery.
8. Conclusion
Cirrhosis is a complex pathology, which involves deregulation at different levels
(Figure 1); some insults such as hepatitis viral infections, alcohol, high fat diet, or
11
Molecular and Cellular Aspects of Cirrhosis and How an Adenosine Derivative Could Revert…
DOI: http://dx.doi.org/10.5772/intechopen.83481
even self-immune events could trigger the development of the illness, denoted by
biochemical alterations like albumin reduction and increase of transaminases. In our
case, we assessed the study of this disease using CCl4, which generates hepatocellu-
lar damage. Once cell membrane is affected by free radicals from CCl4 metabolism,
through epoxide formation, KCs are activated to phagocytose damaged cells; this
activation causes an inflammatory process, due to M1 macrophage activation.
Whether this inflammation is perpetuated, HSCs could be activated, becoming the
main producers of fibrosis (Figure 1B). At molecular level, cirrhotic-damaged liver
loses the capability to proliferate; there is a reduction in DNA methylation, 5hmC,
and histone H4 acetylation, which generates chromosome instability and therefore
alteration of gene expression, affecting principally fibrogenic genes. Among impor-
tant genes involved in the fibrogenic process are Pparg and Col1a1. Cirrhotic liver
presents a compact chromatin context of Pparg gene promoter with the consequent
reduction of both its transcript and protein; on the other hand, Col1a1 gene pro-
moter loses DNA methylation, and this correlates with gene overexpression and the
increment of protein levels. Adenosine derivative, IFC-305, has hepatoprotective
properties (Figure 1C); it is able to reduce fibrosis, ameliorate parenchymal area
and recover liver function. Treatment with this compound polarizes the macro-
phages to an anti-inflammatory phenotype M2, increasing the levels of immuno-
suppressant cytokine IL-10 and arginase 1; the reduction of the inflammatory
process facilitates the inhibition of HSC activation and the consequent reduction of
fibrosis. At molecular level, high serum levels of HGF, principal liver mitogen,
could interact with elevated levels of its receptor, c-Met, and stimulate cell cycle
progression, providing once more the regenerative capacity to the liver. IFC-305
could favor a genome instability diminishment as a consequence of the
Figure 1.
Architectural, physiological, cellular, and molecular alteration during CCl4-induced cirrhosis and
hepatoprotective effects of IFC-305. We show four different analyzed levels in this section: phenotype, denoting
architecture and cell composition of the liver; Serum, biochemical markers related with liver function; cellular
level, changes found in non-parenchymal cells; molecular level, changes in cell cycle components, chromatin,
and gene expression. (A) Healthy liver; (B) CCl4-induced cirrhosis state; (C) pre-established cirrhosis treated
with IFC-305.
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reestablishment of DNA methylation levels and 5hmC and Histone H4 acetylation;
these effects on chromatin trigger the recovery of healthy-like gene expression.
Fibrosis resolution mediated by IFC-305 could be explained by the generation of an
open chromatin context of Pparg gene promoter that correlates with its gene and
protein up-regulation. High levels of PPARγ could act as a repressor of Col1a1
expression in HSC; on the other hand, Col1a1 gene promoter gains DNA methyla-
tion on promoter and TSS, this methylation state goes hand by hand with reduction
of collagen I expression and protein, favoring a decrease in fibrosis, a key point in
cirrhosis resolution. These studies support molecules and cell behavior modified by
IFC-305 as a potential target for new drugs to treat cirrhosis, contribute to the
understanding of liver fibrosis at epigenetic level, open the door to the exploration
of chromatin modifications as a potential biomarker for early detection and inter-
vention of liver diseases, and support the use of IFC-305 as therapy for liver illness.
Finally, we highlight the relationship between cirrhosis and HCC, how liver fibrosis
is the prelude of HCC and in what manner IFC-305 could be an adjuvant preventing
HCC by its anti-cirrhotic and anti-neoplastic effects, and how recent advances
could favor development of an effective treatment, preferring a less invasive to
surgical one.
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Nomenclature
5hmC 5-hydroximethylcytosine
5-LO 5-lipoxygenase
5mC 5-methylcytosine
ALT alanine aminotransferase
AMP adenosine monophosphate
AST aspartate aminotransferase
ATP adenosine triphosphate
CCl3 trichloromethane radical
CCl3OO trichloromethyl peroxy radical
CCl4 carbon tetrachloride
CDK4 cyclin-dependent kinase (for example, CDK4, CDK6, etc.)
c-Met tyrosine-protein kinase Met or hepatocyte growth factor receptor
Col1a1 type I collagen pro-α1(I) chain gene
CpG cytosine guanine dinucleotide
DNA deoxyribonucleic acid
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E2F1 transcription factor E2F1
ECM extracellular matrix
H3K27me3 histone H3 trimethyl lysine 27
H4ac hyperacetylated histone H4
HCC hepatocellular carcinoma
HDAC histone deacetylase
HGF hepatocyte growth factor
HSC hepatic stellate cells
IFC-305 aspartate salt of adenosine: 2-aminosuccinic acid–2-(6-amino-9H-
purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (1:1)
IL interleukin (for example, IL-1β, IL-10, etc.)
iNOS inducible nitric oxide synthase
KC Kupffer cells
LPS lipopolysaccharide
M1 inflammatory macrophages
M2 anti-inflammatory macrophages
MAPK mitogen-activated protein kinase
MCP-1α macrophage protein inflammatory 1-alpha
MeCP2 methyl-CpG binding protein 2
MMP9 matrix metalloproteinase 9
mRNA messenger ribonucleic acid
NO nitric oxide
p21 cyclin-dependent kinase inhibitor 1
p27 cyclin-dependent kinase inhibitor 1B
P450 CYP450 cytochrome
PAMPs pathogen associated molecular patterns
PCNA proliferating cell nuclear antigen
PDGF platelet-derived growth factor
PPARγ peroxisome proliferator-activated receptor gamma
PTMs post-translational modifications
Rb retinoblastoma protein
RNA ribonucleic acid
ROS reactive oxygen species
SAH S-adenosylhomocysteine
SAM S-adenosylmethionine
STAT6 signal transducer and activator of transcription 6
TET DNA dioxygenase ten-eleven translocation
TGF-β transforming growth factor beta
TIMPs tissue inhibitors of matrix metalloproteinases
TLR4 Toll-like receptor 4
TNF-α tumoral necrosis factor alpha
VEGF vascular endothelial growth factor
α-SMA alpha smooth muscle actin.
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